Previous reports have shown that almost all colorectal cancers with BRAF mutation are classified as HMCC [27, 29, 38]; therefore, the inclusion of patients with BRAF mutation may have contributed to the poor clinical outcomes observed in the HMCC group. The gene discussed is BRAF; the disease is colorectal cancer.